Our Mission

Our focus is on directing resources towards innovative therapies, biomarkers, and diagnostics in areas of high need – ranging from infectious diseases to metabolic disorders, and from oncology to neurodegenerative diseases – to generate absolute returns for our investors.
At Danube BioVentures, our mission is to accelerate the discovery and development of pharmaceutical drugs and biomedical innovations, aiming to drive scientific advancement, economic growth, and improved patient outcomes.

Why Early-Stage Funding

It is often difficult to bring breakthroughs from basic academic research to the patient, or “from bench to bed”. After academic funding and before classic seed financing for early clinical trials, there is a gap, often referred to as the “valley of death”. In this transitional phase, when findings from basic research mature into lead compounds for clinical testing, development projects are particularly vulnerable due to insufficient funding.
Danube BioVentures bridges this gap by providing early-stage investment opportunities in carefully selected research projects, aiming for absolute returns to participating shareholders.

Portfolio

Funds